Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.
Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.
复制标题
利妥昔单抗时代滤泡性淋巴瘤患者化疗效果比较研究：日本理赔数据库研究。
作者：
Saaya Tsutsué;K. Tobinai;J. Yi;B. Crawford
目的：评估基于利妥昔单抗 (R) 的疗法与基于非 R 的疗法对日本滤泡性淋巴瘤患者的疗效比较，但日本的研究报道有限。材料和方法：根据患者基线属性和临床特征，使用日本回顾性索赔数据库评估临床和经济结果，将接受基于 R 的指数方案的患者与未接受 R 的患者进行倾向评分匹配。结果与结论：总共 1947 名患者仍留在整个滤泡性淋巴瘤队列中：1294 名患者接受基于 R 的治疗方案，653 名患者接受基于非 R 的治疗方案。接受基于 R 的治疗的患者住院次数较少，住院时间也较短，但在基于 R 的强化治疗的第一年费用较高。临床结果的改善与年轻、女性且在第一个指标中选择基于 R 的方案的患者相关。
Aim: To evaluate comparative effectiveness of rituximub (R)-based versus non-R-based therapies for follicular lymphoma patients in Japan, where limited studies have been reported. Materials & methods: Patients who received R-based index regimens were propensity score matched to those who did not receive R, based on patient baseline attributes and clinical characteristics using Japanese retrospective claims database to assess clinical and economic outcomes. Results & conclusion: A total of 1947 patients remained in the overall follicular lymphoma cohorts: 1294 receiving an R-based and 653 a non-R-based regimen. Patients on R-based therapy underwent fewer hospitalizations and had a shorter length of stay, but had higher costs during the first year of intensive R-based therapy. Improved clinical outcomes were associated with patients who were younger, female and chose R-based regimens in first index line.
影响因子：
20.3
作者：
Krysiak, Kilannin;Gomez, Felicia;Fehniger, Todd A.
通讯作者：
Fehniger, Todd A.